Taking Biosimilars ‘To The Next Level’
IGBA Wants Discussion To Advance On A More Tailored Development Program
The IGBA wants to take discussions around streamlining biosimilar development to “the next level”, the association tells Generics Bulletin.
You may also be interested in...
A week-long global educational initiative to raise awareness of biosimilars has been launched by the IGBA.
A campaign aimed at raising awareness and educating international audiences about biosimilars will be run next week by the IGBA.
The UK drug regulator, the MHRA, has laid out its plans for a biosimilar licensing pathway that will typically not require comparative efficacy data and will consider approved biosimilars interchangeable with their reference products for all indications. The local biosimilars industry believes the guideline creates an opportunity for the UK to be the first launch market for its products.